Skip to main content
Top

03-02-2025 | IL-23 Inhibitor | Research Letter

Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study

Authors: Siddhartha Sood, Alexander Rimke, Brian D. Rankin, Abrahim Abduelmula, Jorge R. Georgakopoulos, Khalad Maliyar, Ahmed Bagit, Fernejoy Leung, Alim R. Devani, Ronald Vender, Jensen Yeung, Vimal H. Prajapati

Published in: American Journal of Clinical Dermatology

Login to get access

Excerpt

In routine clinical practice, biologic switching is common in adult patients with plaque psoriasis [1]. While our group previously reported overall real-world 16-week and 52-week treatment outcomes of bimekizumab, a novel interleukin (IL)-17A/IL-17F inhibitor, limited information exists on switching class from an IL-23 inhibitor (IL-23i) to bimekizumab [2, 3]. This subset analysis of our retrospective cohort study specifically analyzes bimekizumab use following IL-23i exposure. …
Appendix
Available only for authorised users
Literature
3.
go back to reference Sood S, Rimke A, Rankin BD, Abduelmula A, Georgakopoulos JR, Maliyar K, Bagit A, Leung F, Stark LA, Devani AR, Vender R, Yeung J, Prajapati VH. Real-world experience of bimekizumab for adult patients with plaque psoriasis: a 52-week multicenter retrospective study. J Am Acad Dermatol. 2024;91(5):936–9. https://doi.org/10.1016/j.jaad.2024.05.085. (Epub 2024 Jun 15 PMID: 38885841).CrossRefPubMed Sood S, Rimke A, Rankin BD, Abduelmula A, Georgakopoulos JR, Maliyar K, Bagit A, Leung F, Stark LA, Devani AR, Vender R, Yeung J, Prajapati VH. Real-world experience of bimekizumab for adult patients with plaque psoriasis: a 52-week multicenter retrospective study. J Am Acad Dermatol. 2024;91(5):936–9. https://​doi.​org/​10.​1016/​j.​jaad.​2024.​05.​085. (Epub 2024 Jun 15 PMID: 38885841).CrossRefPubMed
4.
go back to reference Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial [published correction appears in Lancet. 2021 Mar 27;397(10280):1182]. Lancet. 2021;397(10273):475–86. https://doi.org/10.1016/S0140-6736(21)00126-4.CrossRefPubMed Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial [published correction appears in Lancet. 2021 Mar 27;397(10280):1182]. Lancet. 2021;397(10273):475–86. https://​doi.​org/​10.​1016/​S0140-6736(21)00126-4.CrossRefPubMed
Metadata
Title
Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study
Authors
Siddhartha Sood
Alexander Rimke
Brian D. Rankin
Abrahim Abduelmula
Jorge R. Georgakopoulos
Khalad Maliyar
Ahmed Bagit
Fernejoy Leung
Alim R. Devani
Ronald Vender
Jensen Yeung
Vimal H. Prajapati
Publication date
03-02-2025
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-025-00922-2